NZ705049A - Respirable cationic dry powders for delivery to the respiratory tract - Google Patents

Respirable cationic dry powders for delivery to the respiratory tract

Info

Publication number
NZ705049A
NZ705049A NZ705049A NZ70504911A NZ705049A NZ 705049 A NZ705049 A NZ 705049A NZ 705049 A NZ705049 A NZ 705049A NZ 70504911 A NZ70504911 A NZ 70504911A NZ 705049 A NZ705049 A NZ 705049A
Authority
NZ
New Zealand
Prior art keywords
respirable
delivery
respiratory tract
dry powders
magnesium lactate
Prior art date
Application number
NZ705049A
Inventor
Michael M Lipp
Jean C Sung
Original Assignee
Pulmatrix Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/049435 external-priority patent/WO2012030664A1/en
Application filed by Pulmatrix Operating Co Inc filed Critical Pulmatrix Operating Co Inc
Publication of NZ705049A publication Critical patent/NZ705049A/en

Links

Abstract

Disclosed is a respirable / inhalable dry powder comprising respirable dry particles that comprise a) magnesium lactate; wherein the magnesium lactate provides divalent metal cation in an amount between 0.1% and 2.9% by weight of the dry particle, and b) a pharmaceutical agent such as albuterol, ciprofloxacin, levofloxacin, tobramycin or tiotropium bromide; wherein the respirable dry particles have a volume median geometric diameter (VMGD) of 5 microns or less; and wherein the composition is preferably for the treatment of a respiratory diseases such as asthma, airway hyperresponsiveness, seasonal allergy, bronchiectasis, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, or cystic fibrosis.
NZ705049A 2010-09-29 2011-09-29 Respirable cationic dry powders for delivery to the respiratory tract NZ705049A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38785510P 2010-09-29 2010-09-29
PCT/US2011/049435 WO2012030664A1 (en) 2010-08-30 2011-08-26 Dry powder formulations and methods for treating pulmonary diseases
NZ60883811 2011-09-29

Publications (1)

Publication Number Publication Date
NZ705049A true NZ705049A (en) 2016-10-28

Family

ID=57207696

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ705049A NZ705049A (en) 2010-09-29 2011-09-29 Respirable cationic dry powders for delivery to the respiratory tract

Country Status (1)

Country Link
NZ (1) NZ705049A (en)

Similar Documents

Publication Publication Date Title
IL256360A (en) Monovalent metal cation dry powders for inhalation
JP2011520911A5 (en)
JP2013540123A5 (en)
JP2013536845A5 (en)
RU2016140347A (en) Aerosol fluoroquinolones and their use
JP2013224331A5 (en)
JP2016065107A5 (en)
MY179703A (en) Dry powder formulation comprising a phosphodiesterase inhibitor
UA107499C2 (en) Dry powder formulation containing an antimuscarinic agent
JP2007505830A5 (en)
MD4369C1 (en) Use of glycopyrrolate for treating tachycardia, unit dose, delivery device, method of treatment and prophylaxis of tachycardia
RU2015146871A (en) DRY POWDERS WITH THIOTROPY
JP2012522009A (en) Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
UA101653C2 (en) Composition for inhalation comprising aclidinium for the treatment of asthma and chronic obstructive pulmonary disease
WO2010111680A3 (en) Dry powder formulations and methods for treating pulmonary diseases
WO2014074797A8 (en) Ultra low density pulmonary powders
WO2006008517A3 (en) Use of dry powder compositions for pulmonary delivery
UA101652C2 (en) Composition for inhalation comprising aclidinium for the treatment of asthma and chronic obstructive pulmonary disease
MY159172A (en) Inhalable particles comprising tiotropium
JP2010508365A5 (en)
RU2014140539A (en) Aggregated Particles
IN2014DN08672A (en)
Kaur Pulmonary drug delivery system: newer patents
NZ705049A (en) Respirable cationic dry powders for delivery to the respiratory tract
UA115989C2 (en) Dry powder inhaler compositions comprising long acting muscorinic antagonists

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 29 SEP 2018 BY DAVIES COLLISON CAVE PTY LTD

Effective date: 20170202

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 SEP 2019 BY CPA GLOBAL

Effective date: 20180816

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 SEP 2020 BY CPA GLOBAL

Effective date: 20190829

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 SEP 2021 BY CPA GLOBAL

Effective date: 20200813

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 SEP 2022 BY THOMSON REUTERS

Effective date: 20210803

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 SEP 2023 BY THOMSON REUTERS

Effective date: 20220801

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 SEP 2024 BY THOMSON REUTERS

Effective date: 20230802